VC-backed Xencor postpones IPO - Fortune

According to Fortune, Xencor has shelved its IPO. No reason was given for the postponement nor was a date rescheduled for the IPO's launch. Xencor had planned on selling 5 million shares of its stock at between $14 and $16 per share. The stock was to slated to trade on the NASDAQ under the ticker symbol “XNCR," with Credit Suisse Securities and Leerink Swann serving as lead underwriters. Based in Monrovia, Calif., Xencor is a biopharmaceutical company that provides engineered monoclonal antibodies to treat autoimmune diseases, asthma, allergic diseases and cancer. It is backed by MedImmune Ventures, Novo Nordisk Biotech Fund, Ronin Capital. Merlin Nexus, Oxford Bioscience Partners and Healthcare Ventures.

North AmericaUSBriefs